Takaisin Tulosta

Dyslipidemiat, näytönastekatsausten kirjallisuusviitteet

Lisätietoa aiheesta
Käypä hoito -toimitus

Kirjallisuusviiteluettelosta löytyy koottuna Käypä hoito -suosituksen Dyslipidemiat «Dyslipidemiat»1 näytönastekatsauksissa arvioitu kirjallisuus.


  1. Abdelhamid AS, Brown TJ, Brainard JS ym. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2018;7:CD003177 «PMID: 30019766»PubMed
  2. ACCORD Study Group., Ginsberg HN, Elam MB ym. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74 «PMID: 20228404»PubMed
  3. AHA., ACC., National Heart, Lung, and Blood Institute. ym. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006;47:2130-9 «PMID: 16697342»PubMed
  4. Alexander DD, Miller PE, Van Elswyk ME ym. A Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies of Eicosapentaenoic and Docosahexaenoic Long-Chain Omega-3 Fatty Acids and Coronary Heart Disease Risk. Mayo Clin Proc 2017;92:15-29 «PMID: 28062061»PubMed
  5. Amarenco P, Bogousslavsky J, Callahan A 3rd ym. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-59 «PMID: 16899775»PubMed
  6. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009;8:453-63 «PMID: 19375663»PubMed
  7. American Diabetes Association.. Standards of medical care in diabetes--2013. Diabetes Care 2013;36 Suppl 1:S11-66 «PMID: 23264422»PubMed
  8. ASCEND Study Collaborative Group., Bowman L, Mafham M ym. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. N Engl J Med 2018;379:1540-1550 «PMID: 30146932»PubMed
  9. Aung PP, Maxwell HG, Jepson RG ym. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev 2007;:CD000123 «PMID: 17943736»PubMed
  10. Baigent C, Keech A, Kearney PM ym. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78 «PMID: 16214597»PubMed
  11. Bhatt DL, Steg PG, Miller M ym. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380:11-22 «PMID: 30415628»PubMed
  12. Braamskamp MJAM, Langslet G, McCrindle BW ym. Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label). Circulation 2017;136:359-366 «PMID: 28592434»PubMed
  13. Bruckert E, Labreuche J, Deplanque D ym. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. J Cardiovasc Pharmacol 2011;57:267-72 «PMID: 21052016»PubMed
  14. Bucher HC, Griffith LE, Guyatt GH. Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. Ann Intern Med 1998;128:89-95 «PMID: 9441587»PubMed
  15. Cannon CP, Blazing MA, Giugliano RP ym. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015;372:2387-97 «PMID: 26039521»PubMed
  16. Cannon CP, Braunwald E, McCabe CH ym. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504 «PMID: 15007110»PubMed
  17. Cannon CP, Steinberg BA, Murphy SA ym. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006;48:438-45 «PMID: 16875966»PubMed
  18. Cholesterol Treatment Trialists' (CTT) Collaborators., Mihaylova B, Emberson J ym. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-90 «PMID: 22607822»PubMed
  19. Cholesterol Treatment Trialists' (CTT) Collaborators., Kearney PM, Blackwell L ym. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-25 «PMID: 18191683»PubMed
  20. Cholesterol Treatment Trialists' Collaboration.. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 2019;393:407-415 «PMID: 30712900»PubMed
  21. Cholesterol Treatment Trialists’ (CTT) Collaboration., Baigent C, Blackwell L ym. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81 «PMID: 21067804»PubMed
  22. Colhoun HM, Betteridge DJ, Durrington PN ym. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96 «PMID: 15325833»PubMed
  23. Collins R, Armitage J, Parish S ym. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16 «PMID: 12814710»PubMed
  24. Collins R, Reith C, Emberson J ym. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016;388:2532-2561 «PMID: 27616593»PubMed
  25. de Lemos JA, Blazing MA, Wiviott SD ym. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-16 «PMID: 15337732»PubMed
  26. Delgado-Lista J, Perez-Martinez P, Lopez-Miranda J ym. Long chain omega-3 fatty acids and cardiovascular disease: a systematic review. Br J Nutr 2012;107 Suppl 2:S201-13 «PMID: 22591894»PubMed
  27. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999;354:447-55 «PMID: 10465168»PubMed
  28. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905-10 «PMID: 11289345»PubMed
  29. Heart Protection Study Collaborative Group.. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22 «PMID: 12114036»PubMed
  30. Heart Protection Study Collaborative Group.. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007;45:645-654; discussion 653-4 «PMID: 17398372»PubMed
  31. Hooper L, Martin N, Abdelhamid A ym. Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev 2015;:CD011737 «PMID: 26068959»PubMed
  32. Hu FB, Manson JE. Omega-3 fatty acids and secondary prevention of cardiovascular disease-is it just a fish tale?: comment on “Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease”. Arch Intern Med 2012;172:694-6 «PMID: 22493410»PubMed
  33. Jakob T, Nordmann AJ, Schandelmaier S ym. Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst Rev 2016;11:CD009753 «PMID: 27849333»PubMed
  34. Jakobsen MU, Dethlefsen C, Joensen AM ym. Intake of carbohydrates compared with intake of saturated fatty acids and risk of myocardial infarction: importance of the glycemic index. Am J Clin Nutr 2010;91:1764-8 «PMID: 20375186»PubMed
  35. Jakobsen MU, O'Reilly EJ, Heitmann BL ym. Major types of dietary fat and risk of coronary heart disease: a pooled analysis of 11 cohort studies. Am J Clin Nutr 2009;89:1425-32 «PMID: 19211817»PubMed
  36. Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ 2008;178:576-84 «PMID: 18299547»PubMed
  37. Joyce NR, Zachariah JP, Eaton CB ym. Statin Use and the Risk of Type 2 Diabetes Mellitus in Children and Adolescents. Acad Pediatr 2017;17:515-522 «PMID: 28232259»PubMed
  38. Keech A, Simes RJ, Barter P ym. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61 «PMID: 16310551»PubMed
  39. Kelley GA, Kelley KS. Impact of progressive resistance training on lipids and lipoproteins in adults: another look at a meta-analysis using prediction intervals. Prev Med 2009;49:473-5 «PMID: 19804794»PubMed
  40. Kelley GA, Kelley KS, Roberts S ym. Comparison of aerobic exercise, diet or both on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. Clin Nutr 2012;31:156-67 «PMID: 22154987»PubMed
  41. Kelley GA, Kelley KS. Effects of Diet, Aerobic Exercise, or Both on Non-HDL-C in Adults: A Meta-Analysis of Randomized Controlled Trials. Cholesterol 2012;2012:840935 «PMID: 23198142»PubMed
  42. Kelley GA, Kelley KS. Impact of progressive resistance training on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. Prev Med 2009;48:9-19 «PMID: 19013187»PubMed
  43. Kodama S, Tanaka S, Saito K ym. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. Arch Intern Med 2007;167:999-1008 «PMID: 17533202»PubMed
  44. Koskinen P, Mänttäri M, Manninen V ym. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992;15:820-5 «PMID: 1516498»PubMed
  45. Kwak SM, Myung SK, Lee YJ ym. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med 2012;172:686-94 «PMID: 22493407»PubMed
  46. LaRosa JC, Deedwania PC, Shepherd J ym. Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial). Am J Cardiol 2010;105:283-7 «PMID: 20102935»PubMed
  47. LaRosa JC, Grundy SM, Waters DD ym. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35 «PMID: 15755765»PubMed
  48. León H, Shibata MC, Sivakumaran S ym. Effect of fish oil on arrhythmias and mortality: systematic review. BMJ 2008;337:a2931 «PMID: 19106137»PubMed
  49. Lin X, Zhang X, Guo J ym. Effects of Exercise Training on Cardiorespiratory Fitness and Biomarkers of Cardiometabolic Health: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc 2015;4: «PMID: 26116691»PubMed
  50. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57 «PMID: 9841303»PubMed
  51. Luirink IK, Wiegman A, Kusters DM ym. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. N Engl J Med 2019;381:1547-1556 «PMID: 31618540»PubMed
  52. Manson JE, Cook NR, Lee IM ym. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. N Engl J Med 2019;380:23-32 «PMID: 30415637»PubMed
  53. Mozaffarian D, Micha R, Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med 2010;7:e1000252 «PMID: 20351774»PubMed
  54. Nuotio K, Soinne L, Hänninen H ym. Life-threatening coronary disease is prevalent in patients with stenosing carotid artery disease. Int J Stroke 2015;10:1217-23 «PMID: 26311319»PubMed
  55. O'Hare F, Spark S, Flanagan Z ym. Impact of informed consent content and length on recruitment of older adults into a community based primary prevention trial. Contemp Clin Trials Commun 2018;11:89-94 «PMID: 30003171»PubMed
  56. O'Keefe JH Jr, Cordain L, Harris WH ym. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 2004;43:2142-6 «PMID: 15172426»PubMed
  57. ORIGIN Trial Investigators., Bosch J, Gerstein HC ym. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012;367:309-18 «PMID: 22686415»PubMed
  58. Palmer SC, Navaneethan SD, Craig JC ym. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2014;:CD007784 «PMID: 24880031»PubMed
  59. Palomäki A , Kovanen P. LDL-kolesterolin luonnonmukainen pitoisuus on saavutettavissa turvallisesti. Duodecim 2006;122;1747-56
  60. Pedersen TR, Faergeman O, Kastelein JJ ym. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45 «PMID: 16287954»PubMed
  61. Perk J, De Backer G, Gohlke H ym. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635-701 «PMID: 22555213»PubMed
  62. Ramos R, García-Gil M, Comas-Cufí M ym. Statins for Prevention of Cardiovascular Events in a Low-Risk Population With Low Ankle Brachial Index. J Am Coll Cardiol 2016;67:630-640 «PMID: 26868687»PubMed
  63. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 1994;344:1383-9 «PMID: 7968073»PubMed
  64. Rizos EC, Ntzani EE, Bika E ym. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012;308:1024-33 «PMID: 22968891»PubMed
  65. Rodenburg J, Vissers MN, Wiegman A ym. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 2007;116:664-8 «PMID: 17664376»PubMed
  66. Rubins HB, Robins SJ, Collins D ym. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002;162:2597-604 «PMID: 12456232»PubMed
  67. Ruppar TM, Conn VS, Chase JA ym. Lipid outcomes from supervised exercise interventions in healthy adults. Am J Health Behav 2014;38:823-30 «PMID: 25207508»PubMed
  68. Sacks FM, Pfeffer MA, Moye LA ym. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9 «PMID: 8801446»PubMed
  69. Saha SA, Arora RR. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials. Int J Cardiol 2010;141:157-66 «PMID: 19232762»PubMed
  70. Sandhu S, Wiebe N, Fried LF ym. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006;17:2006-16 «PMID: 16762986»PubMed
  71. Savarese G, De Ferrari GM, Rosano GM ym. Safety and efficacy of ezetimibe: A meta-analysis. Int J Cardiol 2015;201:247-52 «PMID: 26301648»PubMed
  72. Schwab U, Lauritzen L, Tholstrup T ym. Effect of the amount and type of dietary fat on cardiometabolic risk factors and risk of developing type 2 diabetes, cardiovascular diseases, and cancer: a systematic review. Food Nutr Res 2014;58: «PMID: 25045347»PubMed
  73. Schwingshackl L, Dias S, Hoffmann G. Impact of long-term lifestyle programmes on weight loss and cardiovascular risk factors in overweight/obese participants: a systematic review and network meta-analysis. Syst Rev 2014;3:130 «PMID: 25358395»PubMed
  74. Sever PS, Dahlöf B, Poulter NR ym. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58 «PMID: 12686036»PubMed
  75. Sever PS, Poulter NR, Dahlöf B ym. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care 2005;28:1151-7 «PMID: 15855581»PubMed
  76. Su X, Zhang L, Lv J ym. Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis. Am J Kidney Dis 2016;67:881-92 «PMID: 26905361»PubMed
  77. Taylor F, Huffman MD, Macedo AF ym. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;:CD004816 «PMID: 23440795»PubMed
  78. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64 «PMID: 6361299»PubMed
  79. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-74 «PMID: 6361300»PubMed
  80. Tikkanen MJ, Szarek M, Fayyad R ym. Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. J Am Coll Cardiol 2009;54:2353-7 «PMID: 20082922»PubMed
  81. Wang D, Liu B, Tao W ym. Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst Rev 2015;:CD009580 «PMID: 26497361»PubMed
  82. Wiegman A, Hutten BA, de Groot E ym. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004;292:331-7 «PMID: 15265847»PubMed
  83. Wiviott SD, Cannon CP, Morrow DA ym. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005;46:1411-6 «PMID: 16226163»PubMed
  84. Vuorio A, Kuoppala J, Kovanen PT ym. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev 2019;2019: «PMID: 31696945»PubMed
  85. Yamashita S, Masuda D, Matsuzawa Y. Pemafibrate, a New Selective PPARa Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases. Curr Atheroscler Rep 2020;22:5 «PMID: 31974794»PubMed
  86. Yokoyama M, Origasa H, Matsuzaki M ym. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090-8 «PMID: 17398308»PubMed